Asia 2015: A Tale Of Regulation, Reform And Restructuring
This article was originally published in PharmAsia News
Hopefully the seasonal holidays have provided PharmAsia News's readers with a little time to reflect on the past year and all that it brought in terms of constant change in the commercial and regulatory arenas in Asia's pharma markets. Here's a quick overview of the stories and major themes that garnered most interest to help get you in the swing for the year ahead.
You may also be interested in...
Curon thinks tenalisib can offer a differentiated and safe new therapy for hematologic cancers such as multiple forms of lymphoma. Axis and PharmaEssentia team up on TCR therapy R&D in Taiwan.
Recent moves show Chinese biotech firms are increasingly looking to go global by recruiting world-class development talent, and J&J names new APAC pharma head.
Join us for a brief audio roundup of the major developments in the international biopharma industry over the past week, as covered by Scrip's global team.